EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)

Jürgen Floege, Jonathan Barratt, H Terence Cook, Irene L Noronha, Heather N Reich, Yusuke Suzuki, Sydney C W Tang, Hernán Trimarchi, Ethan M Balk, Craig E Gordon, Gaelen P Adam, Marcello A Tonelli und 2 weitere

Kidney International · 2025-10 · 108 (4) · 548-554

DOI: 10.1016/j.kint.2025.04.003 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Kidney International, 2025-10. Verfasst von Jürgen Floege und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University Hospital, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany. Electronic address: jfloege…. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, IgA Vasculitis, Nephrology. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Immunoglobulin A nephropathy (IgAN) and Immunoglobulin A vasculitis (IgAV) management guideline was last updated and published as part of the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Based on new developments in IgAN assessment and therapy, a major update of the guideline was necessary in 2024. Compared with the last version, the KDIGO 2025 IgAN guideline now encourages a more liberal kidney biopsy policy and suggests aiming for stricter proteinuria control, with a goal of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAIgA VasculitisNephrologyHumansImmunoglobulin ABiopsyProteinuriaGlomerular Filtration RateImmunosuppressive Agents

Stichwörter der Autor:innen

IgA nephropathyIgA vasculitisKDIGOglomerular diseasesglomerulonephritisguideline

Substanzen

Immunoglobulin AImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Nephrology, University Hospital, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Aachen, Germany. Electronic address: jfloege@ukaachen.de.
  • Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
  • Department of Immunology and Inflammation, Imperial College London, London, UK.
  • Renal Division, University of São Paulo Medical School, São Paulo, Brazil.
  • Divsion of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Department of Nephrology, Juntendo University, Tokyo, Japan.

Zitieren

APA

Floege, J., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarchi, H., Balk, E. M., Gordon, C. E., Adam, G. P., Tonelli, M. A., Earley, A., & Rovin, B. H. (2025). Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney International, 108(4), 548-554. https://doi.org/10.1016/j.kint.2025.04.003

Vancouver

Floege J, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney International. 2025;108(4):548-554. doi:10.1016/j.kint.2025.04.003

BibTeX
@article{Floege2025,
  author = {Floege, Jürgen and Barratt, Jonathan and Cook, H Terence and Noronha, Irene L and Reich, Heather N and Suzuki, Yusuke and Tang, Sydney C W and Trimarchi, Hernán and Balk, Ethan M and Gordon, Craig E and Adam, Gaelen P and Tonelli, Marcello A and Earley, Amy and Rovin, Brad H},
  title = {Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)},
  journal = {Kidney International},
  year = {2025},
  volume = {108},
  number = {4},
  pages = {548--554},
  doi = {10.1016/j.kint.2025.04.003}
}
Kostenlos starten →